Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04241718 · ClinicalTrials.gov registry record · NA
A Feasibility Study on Ultrafiltration and Blood Volume Measurements
A NA study, sponsored by Nuwellis.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT04241718 is a NA study that was terminated before completion, run by Nuwellis. The registered enrollment target is 6 participants.
The verdict
NCT04241718, a NA study, was terminated before completion, sponsored by Nuwellis.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of this feasibility study is to characterize the performance of the Aquadex FlexFlow® System with the hematocrit (HCT) feature in conjunction with Daxor's blood volume analyzer (BVA-100). The study will monitor blood volume changes during ultrafiltration (UF) therapy as a potential means to guide the removal of fluid in subjects hospitalized with acute decompensated heart failure (ADHF).
Interventions
- DEVICE Aquadex FlexFlow System and BVA-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2022-12-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04241718
The ClinicalTrials.gov registry entry for NCT04241718 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nuwellis, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aquadex FlexFlow System and BVA-100 is the first listed.
NCT04241718 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04241718 about?
NCT04241718 is a clinical study titled "A Feasibility Study on Ultrafiltration and Blood Volume Measurements". The objective of this feasibility study is to characterize the performance of the Aquadex FlexFlow® System with the hematocrit (HCT) feature in conjunction with Daxor's blood volume analyzer (BVA-100). The study will monitor blood volume changes during ultrafiltration (UF) therapy as a potential mea...
What is the current status of trial NCT04241718?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2019-12-19. Estimated completion is 2022-12-27.
What interventions are being tested in trial NCT04241718?
The interventions under investigation include: Aquadex FlexFlow System and BVA-100 (DEVICE).
Who is sponsoring clinical trial NCT04241718?
This trial is sponsored by Nuwellis, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.